NCT00692133
Completed
N/A
Spanish Validation of Tool Questionnaire to Assess Patients´Perception About Antipsychotic Treatment
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Schizophrenia
- Sponsor
- AstraZeneca
- Enrollment
- 250
- Locations
- 1
- Primary Endpoint
- TOOL questionnaire
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
Non-interventional, prospective study to validate Spanish version of TOOL questionnaire in patients with schizophrenia and bipolar disorder under antipsychotic treatment
Investigators
Eligibility Criteria
Inclusion Criteria
- •Schizophrenia and bipolar disorder (DSM-IV criteria)
- •Stabilized out-patients
- •Treated with the same oral antipsychotic at least in the last month
Exclusion Criteria
- •Participation in another clinical trial within 6 months prior to enrolment into this study
- •Administration of a depot antipsychotic medication
Outcomes
Primary Outcomes
TOOL questionnaire
Time Frame: 15 days
PANSS & Young Mania Scale
Time Frame: 15 days
Secondary Outcomes
- Montgomery Asberg Depression Scale(15 days)
- Euroqol 5D & SF-36D(performed only at baseline visit)
- UKU modified scale(performed only at baseline visit)
Study Sites (1)
Loading locations...
Similar Trials
Completed
N/A
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)CancerNCT01436240Memorial Sloan Kettering Cancer Center112
Completed
N/A
Spanish-language Version of the Kihon ChecklistFrailtyNCT04152070University of Valencia251
Completed
N/A
Validation of the Spanish Version of the Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM) in ChilePsychological DistressNCT04122079Pontificia Universidad Catolica de Chile1,120
Completed
N/A
Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With SchizophreniaSchizophreniaSchizoaffective DisorderSchizophreniform DisorderNCT00749970AstraZeneca100
Completed
N/A
Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETsGastroenteropancreatic Neuroendocrine TumorsNCT02630654Ipsen404